Jeffrey Miller

Jeffrey S. Miller, MD, is a Professor of Medicine at the University of Minnesota Medical School and Deputy Director of the Masonic Cancer Center. He is known for turning natural killer (NK) cells — immune cells that attack tumor cells on first contact — into a practical cancer therapy platform. His field is cancer immunotherapy, not natural resources: he has no commodity or mining track record, and his presence in Pixys content stems from one biotech connection, GT Biopharma (GTBP), whose TriKE technology he co-invented.

Miller's record is measurable. In 2005 he led the study, published in Blood, that first showed donor NK cells could be transferred into cancer patients and expand in the body — a foundation for today's NK cell therapy field. With his University of Minnesota colleague Martin Felices, he invented the TriKE (Tri-specific Killer cell Engager), a single engineered molecule that recruits NK cells to tumor cells. The University of Minnesota licensed the platform to GT Biopharma, where Miller serves as Consulting Senior Medical Director. The first TriKE candidate, GTB-3550, entered a first-in-human Phase I/II trial in relapsed or refractory AML (acute myeloid leukemia — an aggressive cancer of blood-forming cells) and high-risk MDS (myelodysplastic syndromes — bone marrow disorders that can progress to leukemia). A second-generation candidate, GTB-3650, is now in a Phase 1 trial for the same diseases.

His method is translational: design a molecule in the lab, show it works in disease models, then test it first in humans in blood cancers, where bone marrow samples let researchers measure whether the therapy reaches its target. The TriKE design has three arms — one binds CD16, the receptor that activates NK cells; one binds CD33, a marker on leukemia cells; and one carries IL-15, a growth signal that expands NK cells without broadly stimulating T cells, which reduces the risk of immune overreaction.

For investors, following Miller means following GT Biopharma's clinical milestones: GTB-3650's Phase 1 enrollment and safety readouts, with the next data expected in 2026, plus a separate Phase 1 program in solid tumors. What he offers is authority on NK cell science and trial design — not on metals, mining, or macro. Resource investors should treat his profile as biotech context only: his opinions carry weight in immunotherapy, and nowhere else.